T3D Therapeutics
T3D Therapeutics, a US-based company, is developing a potential breakthrough Alzheimer's treatment to slow or reverse the disease.
Founded
2013T3D Therapeutics, a US-based company, is developing a potential breakthrough Alzheimer's treatment to slow or reverse the disease.
T3D Therapeutics, founded in Durham, United States, is dedicated to developing innovative treatments for Alzheimer's disease. The company's core mission is to advance its lead drug candidate, T3D-959, which aims to be a 'First-in-Class' and 'Best-in-Class' disease-modifying therapy. T3D-959 is designed to potentially slow, stop, or reverse the progression of Alzheimer's, offering a transformative approach to neurodegenerative disease treatment. The company focuses on leveraging metabolic approaches to address the underlying causes of Alzheimer's.
Notable figures associated with T3D Therapeutics include a distinguished management team and a scientific advisory board comprising experts in neurodegenerative diseases. The company has garnered attention for its promising pipeline and has achieved significant milestones in preclinical and clinical trials. T3D Therapeutics' impact lies in its potential to revolutionize Alzheimer's treatment, providing hope for millions affected by the disease and contributing to the broader field of neurodegenerative research.
Companies similar to T3D Therapeutics include TNeuroPharma, Arkuda Therapeutics, Alzheon and Denali Therapeutics.
T3D Therapeutics was founded in 2013.
T3D Therapeutics' headquarters is located in Durham, NC, US.
T3D Therapeutics' most recent funding round was for $6M (USD) in September 2022.
As of Sep 3, 2022, T3D Therapeutics has disclosed funding of $40.3M (USD). Undisclosed round amounts are excluded.
T3D Therapeutics has 14 employees as of Feb 5, 2024.
Denali Therapeutics
